



Windsor Cancer Research Group

2nd Biennial

**INTERNATIONAL CANCER RESEARCH
CONFERENCE**



NOVEMBER 22, 2014

Caesars Windsor Convention Centre

Windsor – Ontario – Canada





www.windsorcancerresearch.ca

CONFERENCE OVERVIEW

8:00 am	Registration, light breakfast and poster set up	LOBBY & AUGUSTUS II
8:45 am	Welcome	AUGUSTUS II
9:00 am	Opening Keynote Address: HAS ANYONE EVER ACTUALLY BEEN HARMED BECAUSE OF A BREACH OF PROPERLY DE-IDENTIFIED HEALTH RESEARCH DATA? <i>Dr. Craig Earle, Ontario Institute for Cancer Research (OICR)</i>	AUGUSTUS II
10:00 am – 12 pm	Joint Session Moderators: <i>Caroline Hamm, WCRG, Windsor Regional Cancer Centre and Dora Cavallo-Medved, WCRG, University of Windsor</i>	AUGUSTUS II
12:15 pm	Lunch	AUGUSTUS II
1:30 – 3:30 pm	Concurrent Break Out Session A Moderators: <i>Swati Kulkarni, WCRG, Windsor Regional Cancer Centre and Glenn Bauman, London Regional Cancer Program at Victoria Hospital and Schulich School of Medicine and Dentistry at Western University</i>	MERCURI
1:30 – 3:30 pm	Concurrent Break Out Session B Moderators: <i>Otis Vacratsis, WCRG, University of Windsor and Gabriel DiMattia, London Regional Cancer Centre</i>	MARTIS
4:00 – 5:55 pm	Poster session	AUGUSTUS I
6:00 pm	Banquet featuring Keynote Address: THE FALLOPIAN TUBE AS A PLATFORM FOR UNDERSTANDING OVARIAN CANCER PATHOGENESIS AND DRIVING DRUG DISCOVERY <i>Dr. Ron Drapkin, Dana-Farber Cancer Institute</i>	AUGUSTUS II

www.windsorcancerresearch.ca

KEYNOTE SPEAKERS



Dr. Craig Earle, MD, M.Sc.

Program Director, Health Services Research, Ontario Institute for Cancer Research (OICR)

Dr. Craig Earle is a medical oncologist specializing in gastrointestinal cancers at Sunnybrook's Odette Cancer Centre, a Professor of Medicine at the University of Toronto and a Senior Scientist at the Institute for Clinical Evaluative Sciences. Dr. Earle received his B.Sc. in Biochemistry in 1989, his M.D. in 1990, and his M.Sc. in Epidemiology in 1998 from the University of Ottawa. In 1998, he moved to Boston where he was an Associate Professor of Medicine at Harvard Medical School and Associate Professor of Health Policy and Management at the Harvard School of Public Health. While there, he was the founding Director of the Lance Armstrong Foundation Adult Survivorship Clinic at Dana-Farber Cancer Institute. Dr. Earle returned to Ontario in 2008 to be the Director of Health Services Research for Cancer Care Ontario and the Ontario Institute for Cancer Research, a joint effort to enhance Ontario's capacity to study how the organization and delivery of its cancer services affects the quality and outcomes of care. He also currently serves as Chair of the Ontario Steering Committee for Cancer Drug Programs. His personal research interests focus on evaluating and improving the quality of care received by patients with advanced cancer and cancer survivors, the effect of financial incentives on care delivery, and making linked de-identified administrative data more available for health research.



Dr. Ronny Drapkin, MD, Ph.D.

Principal Investigator, Medical Oncology, Dana-Farber Cancer Institute

Dr. Ronny Drapkin is an Associate Professor at Harvard Medical School, an Associate Pathologist at Brigham and Women's Hospital and a Principle Investigator at the Dana-Farber Cancer Institute. Dr. Drapkin received his B.A. in Biochemistry from Brandeis University in 1990 and his M.D. and Ph.D. from the Rutgers Health Sciences - Robert Wood Johnson Medical School in 1998. He completed his residency in Anatomic Pathology at Brigham and Women's Hospital in 2001 and a postdoctoral fellowship at the Dana-Farber Cancer Institute in 2006. He joined the faculty at Harvard in 2006. Dr. Drapkin serves on the editorial boards of *Clinical Cancer Research* and *Gynecologic Oncology* and his laboratory is funded by NIH/NCI grants, foundations and philanthropic gifts. Research in the Drapkin laboratory focuses on developing a comprehensive understanding of cancer pathogenesis, DNA repair mechanisms, and genomics of women's cancers with a special focus on ovarian carcinomas. The ultimate goal is to translate important principles discovered in the laboratory into clinical useful diagnostic and therapeutic tools.

CONFERENCE PROGRAM SCHEDULE

8:00 am	Registration, light breakfast and poster set up	LOBBY & AUGUSTUS II
8:45 am	Welcome	AUGUSTUS II
9:00 am	Opening Keynote Address: HAS ANYONE EVER ACTUALLY BEEN HARMED BECAUSE OF A BREACH OF PROPERLY DE-IDENTIFIED HEALTH RESEARCH DATA? <i>Dr. Craig Earle, Ontario Institute for Cancer Research (OICR)</i>	AUGUSTUS II
10:00 am – 12:00 pm	Joint Session <i>Moderators: Caroline Hamm, WCRG, Windsor Regional Cancer Centre and Dora Cavallo-Medved, WCRG, University of Windsor</i> ABSTRACT O1 KISS1R SIGNALLING IN TRIPLE NEGATIVE BREAST CANCER Moshmi Bhattacharya Presenter Affiliation: Western University, Department of Physiology and Pharmacology, Oncology ABSTRACT O2 “IT IS NOT EASY, THEREFORE A LOT OF PEOPLE THEY DO NOT WANT TO GO”: EXAMINING THE CANCER SCREENING PRACTICES FOR MUSLIM WOMEN Jamie Crawley Presenter Affiliation: University of Windsor, Faculty of Nursing, ABSTRACT O3 PERSONALIZED CANCER THERAPY: ARMED SERIAL KILLER T CELLS AS CANCER VACCINES Lawrence Lum Presenter Affiliation: Wayne State University and Karmanos Cancer Institute ABSTRACT O4 TUMOR ASSOCIATED MONOCYTES AUGMENT INVASION OF INFLAMMATORY BREAST CANCER CELLS VIA PROTEOLYTIC ACTIVITY AND EPITHELIAL MESENCHYMAL TRANSITION-DEPENDENT MECHANISMS Mona Mostafa Mohamed Presenter Affiliation: Faculty of Science, Cairo University, Giza, Egypt	AUGUSTUS II

ABSTRACT O5

**COMPLEXITY OF NATURAL HEALTH PRODUCTS: GOOD OR BAD?
ANTICANCER ACTIVITY OF LONG PEPPER EXTRACT (POLYCHEMICAL
MIXTURE) VERSUS PURE PIPERLONGUMINE**

Siyaram Pandey

Presenter Affiliation: Department of Chemistry and Biochemistry,
University of Windsor

12:15 pm

Lunch

AUGUSTUS II

**1:30 –
3:30 pm**

Concurrent Break Out Session A

MERCURI

***Moderators:** Swati Kulkarni, WCRG, Windsor Regional Cancer Centre
and Glenn Bauman, London Regional Cancer Program at Victoria
Hospital and Schulich School of Medicine and Dentistry at Western
University*

ABSTRACT O6

**OUTCOMES OF PATIENTS WITH TRIPLE NEGATIVE BREAST CANCER
COMPARED TO NON-TRIPLE NEGATIVE BREAST CANCER. A SINGLE
CENTRE STUDY**

Caroline Hamm

Presenter Affiliation: Schulich School of Medicine, University of
Windsor and Windsor Cancer Research Group

ABSTRACT O7

**USE AND IMPACT OF INTERMITTENT VERSUS CONTINUOUS
SYSTEMIC TREATMENT STRATEGIES IN METASTATIC COLORECTAL
CANCER IN ROUTINE PRACTICE**

Amin Kay

Presenter Affiliation: Windsor Regional Cancer Centre and University
of Toronto

ABSTRACT O8

**FIRST NATIONS AND MÉTIS PEOPLES' PERSPECTIVES AND
EXPERIENCES CONCERNING CANCER SCREENING IN
SOUTHWESTERN ONTARIO**

Heather Krohn

Presenter Affiliation: Faculty of Nursing, University of Windsor

ABSTRACT O9

INTENSITY MODULATED RADIOTHERAPY IMPROVED HEAD AND NECK CANCER OUTCOME IN WINDSOR ONTARIO

Ming Pan

Presenter Affiliation: Windsor Regional Hospital Cancer Program

ABSTRACT O10

TREATMENT OUTCOMES OF PATIENTS DURING THE FIRST 10 YEARS OF THE WINDSOR REGIONAL CANCER CENTRE HIGH-DOSE-RATE (HDR) PROSTATE BRACHYTHERAPY PROGRAM

Colvin Springer

Presenter Affiliation: Windsor Regional Hospital

ABSTRACT O11

CT-PERFUSION MEASUREMENTS AS A PREDICTOR OF PATIENT OUTCOME FOR TRANSARTERIAL CHEMOEMBOLIZATION (TACE) OF LIVER TUMORS

Mark Dekaban

Presenter Affiliation: Department of Medical Biophysics, University of Western Ontario; Imaging Research Labs, Robarts Research Institute

**1:30 –
3:30 pm**

Concurrent Break Out Session B

MARTIS

***Moderators:** Otis Vacratsis, WCRG, University of Windsor and Gabriel DiMattia, London Regional Cancer Centre*

ABSTRACT O12

SOLID LIPID NANOPARTICLES AS CHEMO PREVENTIVE TOPICAL DELIVERY SYSTEM IN SKIN CANCER MICE MODEL.

Tranum Kaur

Presenter Affiliation: Department of Chemistry and Biochemistry, University of Windsor

ABSTRACT O13

STUDYING TUMOUR METABOLISM; USING HYPERPOLARIZED ¹³C PYRUVATE MAGNETIC RESONANCE IMAGING.

Heeseung Lim

Presenter Affiliation: Medical Biophysics, Western University